CAS: 1702259-66-2

H3B-6527 is a novel, potent and reversible CDK4/6 inhibitor that has been shown to inhibit the proliferation of cervical cancer cells in culture. H3B-6527 is a covalent, irreversible inhibitor of CDK4/6 that has been shown to be active in vitro. This agent induces cell death by increasing autophagy and inhibiting protein synthesis, resulting in a reduced tumor burden in vivo. In addition, H3B-6527 has been shown to have no effect on healthy kidney cells and does not cause any adverse effects when tested in vivo. Clinical studies are currently underway to evaluate the efficacy and safety of H3B-6527 as an anticancer drug.

H3B-6527

H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma, with antineoplastic activity.